127 related articles for article (PubMed ID: 2830043)
1. First-line chemotherapy rechallenge after relapse in small cell lung cancer.
Vincent M; Evans B; Smith I
Cancer Chemother Pharmacol; 1988; 21(1):45-8. PubMed ID: 2830043
[TBL] [Abstract][Full Text] [Related]
2. Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients.
Jacot W; Pujol JL; Chakra M; Molinier O; Bozonnat MC; Gervais R; Quantin X
Lung Cancer; 2012 Feb; 75(2):213-6. PubMed ID: 21831476
[TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
4. Second-line chemotherapy for relapsed small cell lung cancer.
Ebi N; Kubota K; Nishiwaki Y; Hojo F; Matsumoto T; Kakinuma R; Ohmatsu H; Sekine I; Yokosaki M; Gotoh K; Yamamoto H; Kodama T
Jpn J Clin Oncol; 1997 Jun; 27(3):166-9. PubMed ID: 9255271
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer.
Froeschl S; Nicholas G; Gallant V; Laurie SA
J Thorac Oncol; 2008 Feb; 3(2):163-9. PubMed ID: 18303438
[TBL] [Abstract][Full Text] [Related]
7. Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Naito Y; Yamada K; Imamura Y; Ishii H; Matsuo N; Tokito T; Kinoshita T; Azuma K; Hoshino T
Med Oncol; 2018 Apr; 35(5):61. PubMed ID: 29610997
[TBL] [Abstract][Full Text] [Related]
8. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base.
Albain KS; Crowley JJ; Hutchins L; Gandara D; O'Bryan RM; Von Hoff DD; Griffin B; Livingston RB
Cancer; 1993 Aug; 72(4):1184-91. PubMed ID: 8393365
[TBL] [Abstract][Full Text] [Related]
9. Long term survival of small cell lung cancer patients after chemotherapy.
van der Gaast A; Postmus PE; Burghouts J; van Bolhuis C; Stam J; Splinter TA
Br J Cancer; 1993 Apr; 67(4):822-4. PubMed ID: 8385981
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Wakuda K; Kenmotsu H; Naito T; Akamatsu H; Ono A; Shukuya T; Nakamura Y; Tsuya A; Murakami H; Takahashi T; Endo M; Nakajima T; Yamamoto N
Am J Clin Oncol; 2015 Feb; 38(1):28-32. PubMed ID: 23388567
[TBL] [Abstract][Full Text] [Related]
11. Effective combination chemotherapy of carboplatin and paclitaxel in the treatment of a recurrent small-cell lung cancer patient.
Kaira K; Ishizuka T; Yanagitani N; Sunaga N; Hisada T; Mori M
Gan To Kagaku Ryoho; 2007 Feb; 34(2):225-7. PubMed ID: 17301532
[TBL] [Abstract][Full Text] [Related]
12. Radiation therapy for chest recurrences following induction chemotherapy in small cell lung cancer.
Salazar OM; Yee GJ; Slawson RG
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):645-50. PubMed ID: 1651305
[TBL] [Abstract][Full Text] [Related]
13. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
Leighl NB; Goss GD; Lopez PG; Burkes RL; Dancey JE; Rahim YH; Rudinskas LC; Pouliot JF; Rodgers A; Pond GR; Shepherd FA
Lung Cancer; 2006 Jun; 52(3):327-32. PubMed ID: 16597474
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
Shepherd FA; Evans WK; MacCormick R; Feld R; Yau JC
Cancer Treat Rep; 1987 Oct; 71(10):941-4. PubMed ID: 2820571
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients.
Kim GM; Kim YS; Ae Kang Y; Jeong JH; Kim SM; Hong YK; Sung JH; Lim ST; Kim JH; Kim SK; Cho BC
J Thorac Oncol; 2012 Apr; 7(4):731-6. PubMed ID: 22425922
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.
Schmittel A; Knödler M; Hortig P; Schulze K; Thiel E; Keilholz U
Lung Cancer; 2007 Jan; 55(1):109-13. PubMed ID: 17097191
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung.
Remick SC; Neville AJ; Willson JK
Cancer Treat Rep; 1987 Jun; 71(6):575-80. PubMed ID: 3034422
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]